Rockefeller Capital Management L.P. Sells 147,931 Shares of Astrazeneca Plc $AZN

Rockefeller Capital Management L.P. cut its holdings in shares of Astrazeneca Plc (NYSE:AZN) by 18.4% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 654,439 shares of the company’s stock after selling 147,931 shares during the quarter. Rockefeller Capital Management L.P.’s holdings in Astrazeneca were worth $114,854,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Brighton Jones LLC boosted its position in Astrazeneca by 93.2% during the fourth quarter. Brighton Jones LLC now owns 5,782 shares of the company’s stock valued at $379,000 after buying an additional 2,789 shares during the period. AQR Capital Management LLC increased its holdings in shares of Astrazeneca by 45.3% in the first quarter. AQR Capital Management LLC now owns 37,501 shares of the company’s stock worth $2,756,000 after buying an additional 11,690 shares during the period. Amundi lifted its stake in shares of Astrazeneca by 54.4% in the 2nd quarter. Amundi now owns 10,274 shares of the company’s stock valued at $731,000 after acquiring an additional 3,618 shares during the last quarter. Jump Financial LLC lifted its stake in shares of Astrazeneca by 898.4% in the 2nd quarter. Jump Financial LLC now owns 33,478 shares of the company’s stock valued at $2,339,000 after acquiring an additional 30,125 shares during the last quarter. Finally, Daiwa Securities Group Inc. boosted its holdings in Astrazeneca by 1.2% during the 2nd quarter. Daiwa Securities Group Inc. now owns 46,642 shares of the company’s stock valued at $3,259,000 after acquiring an additional 559 shares during the period. 20.35% of the stock is currently owned by institutional investors.

Astrazeneca Trading Down 0.0%

NYSE AZN opened at $174.87 on Friday. The stock has a market cap of $271.20 billion, a P/E ratio of 26.26, a price-to-earnings-growth ratio of 1.52 and a beta of 0.25. Astrazeneca Plc has a fifty-two week low of $137.23 and a fifty-two week high of $212.71. The stock has a 50 day simple moving average of $186.62 and a two-hundred day simple moving average of $186.27. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.71 and a current ratio of 0.91.

Astrazeneca (NYSE:AZN) last posted its earnings results on Wednesday, April 29th. The company reported $2.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.52 by $0.06. The firm had revenue of $15.29 billion for the quarter, compared to analysts’ expectations of $14.93 billion. Astrazeneca had a return on equity of 30.86% and a net margin of 17.19%. On average, analysts forecast that Astrazeneca Plc will post 9.39 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the company. DZ Bank raised Astrazeneca from a “neutral” rating to a “buy” rating in a research note on Wednesday, April 29th. Wall Street Zen raised shares of Astrazeneca from a “hold” rating to a “buy” rating in a research note on Saturday, May 2nd. UBS Group reiterated a “buy” rating on shares of Astrazeneca in a report on Friday, April 10th. Jefferies Financial Group reissued a “buy” rating on shares of Astrazeneca in a research report on Tuesday, June 9th. Finally, TD Cowen reissued a “buy” rating on shares of Astrazeneca in a report on Wednesday, March 18th. Twelve equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $205.33.

About Astrazeneca

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.